Edition:
India

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

671.67GBp
4:09pm IST
Change (% chg)

-8.33 (-1.23%)
Prev Close
680.00
Open
678.50
Day's High
687.50
Day's Low
667.50
Volume
123,371
Avg. Vol
644,363
52-wk High
738.50
52-wk Low
528.36

Chart for

About

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and... (more)

Overall

Beta: 0.11
Market Cap(Mil.): £2,626.84
Shares Outstanding(Mil.): 386.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.47 15.77
EPS (TTM): -- -- --
ROI: -- 14.26 15.19
ROE: -- 15.57 13.80

BTG ordered to pay damages of $55.8 mln to Wellstat

LONDON, Sept 20 British drugs company BTG has been ordered to pay damages of $55.8 million plus interest and costs to Wellstat Therapeutics in a dispute over the distribution of Vistogard, an antidote to the overdose of two chemotherapy drugs.

20 Sep 2017

BRIEF-BTG ordered to pay damages of $55.8 mln to Wellstat Therapeutics

* ‍a memorandum opinion has been issued against btg in its previously announced litigation with wellstat therapeutics corporation​

20 Sep 2017

BRIEF-Integrated Capital Services says board approves appointment of Bhavesh Chadha as CFO

* Incorporating wholly owned subsidiary company BTG IP Services Pvt. Ltd

20 Jul 2017

BRIEF-BTG says trading since April 1 in line with expectations

* Our strong performance in 2016/17 has continued into new financial year

13 Jul 2017

BTG's pulmonary embolism device work faster and at lower doses in study

LONDON British pharmaceutical firm BTG said on Monday its EKOS combination therapy device for pulmonary embolism (PE) was effective using smaller drug dosages and shorter treatment periods than the current standard.

22 May 2017

BTG's pulmonary embolism device work faster and at lower doses in study

LONDON, May 22 British pharmaceutical firm BTG said on Monday its EKOS combination therapy device for pulmonary embolism (PE) was effective using smaller drug dosages and shorter treatment periods than the current standard.

22 May 2017

BRIEF-BTG updates on Optalyse pulmonary embolism study results

* Optalyse PE study demonstrates safety and efficacy of shorter, lower dose Ekos ® therapy for pulmonary embolism

22 May 2017

BRIEF-BTG sees double-digit product sales growth in medium term

* Are well positioned to capture further value in growing interventional medicine space and to deliver sustained business growth

16 May 2017

Earnings vs. Estimates